UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | ||
(Address of Principal Executive Offices, including zip code) | ||||
Registrant’s telephone number, including area code: ( | ||||
Not Applicable | ||||
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class | Trading Symbol | Name of each exchange on which registered | |
The | |||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐
|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Management Retention Agreements
On July 5, 2023, Lantronix, Inc. (the “Company”) entered into a form of retention letter agreement (the “Retention Agreement”) with certain of its executive officers, including Jeremy Whitaker, Interim Chief Executive Officer and Chief Financial Officer, Roger Holliday, Vice President of Worldwide Sales, and Eric Bass, Vice President of Research and Development, providing for severance benefits in the event that the Company terminates the executive’s employment with the Company under certain conditions described below.
The Retention Agreement provides that if, at any time prior to the Determination Date (as defined in the Retention Agreement), the Company terminates the executive’s employment for any reason other than for Cause (as defined in the executive’s employment offer letter from the Company and other than due to the executive’s death or disability), the executive will be entitled to (i) continue the executive’s status as an employee of the Company with full pay and all other benefits, even if the executive is not required to come to work or perform any tasks, from the time the executive receives notice of the Company’s decision to terminate his or her employment (the “Notice Date”) through the actual Termination Date (as defined in the Retention Agreement); (ii) the executive’s bonus for fiscal year 2024 (if any, and to the extent not otherwise paid or payable), to be determined and paid as though the executive had continued to be employed with the Company through the applicable payment date, with such payment to be made not later than two weeks after the public announcement of the Company’s final audited financial results for fiscal year 2024; and (iii) vesting of the executive’s performance stock unit awards for the Company’s fiscal years 2022, 2023 and 2024, as applicable (collectively, the “Grants”), with respect to any performance periods under the Grants scheduled to end in fiscal year 2024, with such vesting to be determined based on the Company’s actual performance during the applicable performance period and as though the executive had continued to be employed with the Company through the date of actual receipt of shares pursuant to the Grants, or through the Determination Date if the Compensation Committee of the Board of Directors determines that vesting shall not occur because the performance targets for fiscal year 2024 under each Grant were not met; provided, that if the executive is provided notice of termination during fiscal year 2024, he or she will not be entitled to any vesting with respect to a performance period scheduled to end after fiscal year 2024.
Under the Retention Agreement, “Termination Date” is defined as, and the executive’s employment with the Company will be terminated on, the day after the executive receives shares pursuant to the Grants for performance targets for fiscal year 2024, or notice that a determination was made by the Company’s Board of Directors or applicable committee thereof that the performance targets for that fiscal year under each Grant were not met; and “Determination Date” is defined as the date on which the Company’s Board of Directors or applicable committee makes the vesting determination under the Grants with respect to the performance periods thereunder ending with or in fiscal year 2024, to occur no later than the earlier of the date on which the Company announces its audited financial results for fiscal year 2024 or 2½ months after the end of fiscal year 2024.
The benefits in the Retention Agreement are supplemental to, and do not replace or amend, any existing agreement between the executive and the Company, including the terms of any Grant document (other than as expressly provided in the Retention Agreement); provided, however, that if in the period between the Notice Date and the Termination Date the executive is not required to come to work or perform any tasks for a period of six months or more, he or she will not receive any additional severance pay upon the executive’s separation from the Company pursuant to any Company policy or practice other than in the event of a change in control of the Company, in which event the severance provisions of the executive’s employment offer letter from the Company or change in control agreement, if applicable, will continue to apply in accordance with and subject to their applicable terms.
The foregoing description of the Retention Agreement is a summary, does not purport to be complete and is qualified in its entirety by reference to the Retention Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed with this Current Report on Form 8-K:
Exhibit No. |
Description | |
10.1 | ||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LANTRONIX, INC. | |||
By: | /s/ Jeremy Whitaker | ||
Jeremy Whitaker Interim Chief Executive Officer and Chief Financial Officer |
Date: July 5, 2023
3 |
Exhibit 10.1
July 5, 2023
Via Email
[Full Name]
Lantronix, Inc.
48 Discovery, Suite 250
Irvine, California 92618
Email: [Email address]
Re: Retention Letter Agreement
Dear [Select Name Prefix] [Last Name],
The Compensation Committee of the Board of Directors of Lantronix, Inc (the “Company”) is very pleased with your continued dedication to the Company, and would like, by this letter, to demonstrate the Company’s commitment to you.
Reference is hereby made to that certain: (A) Notice of Grant of Performance Stock Unit Award, dated Click or tap to enter a date. (the “FY22 Grant”); (B) Notice of Grant of Performance Stock Unit Award, dated Click or tap to enter a date. (the “FY23 Grant”); and (C) the Final Form of Notice of Grant of Performance Stock Unit Award that we issued to you on July 3, 2023 (the “FY24 Grant” and, together with the FY22 Grant and the FY23 Grant, collectively referred to as the “Grants” and each a “Grant”). Reference is also made to your employment offer letter from the Company dated Click or tap to enter a date. (the “Employment Letter”).
If the Company decides to terminate your employment for any reason other than for Cause (as such term is defined in the Employment Letter; and for clarity, other than due to your death or disability) before the Determination Date (as defined below), then you will be entitled to the following:
· | You will be entitled to continue your status as an employee of the Company, with full pay and all other benefits (even though you may not be required to come to work or perform any tasks) from the time you receive notice of the Company’s decision to terminate your employment (the “Notice Date”) through the actual Termination Date (as defined below). | |
· | You will be entitled to your Company bonus for fiscal year 2024 (if any, and to the extent not otherwise paid or payable), to be determined and paid as though you had continued to be employed with the Company through the applicable payment date. Such payment will be made not later than two weeks after the public announcement of the audited results for fiscal year 2024. | |
· | You will be entitled to vest your equity awards on account of each of the Grants to the extent any of the performance periods under the Grants scheduled to end in fiscal year 2024, with such vesting to be determined based on the Company’s actual performance during the applicable performance period and as though you had continued to be employed with the Company through the date of actual receipt of shares of the Company on account of such vested Grants or through the Determination Date if the Compensation Committee determined that vesting shall not occur because the performance targets for FY24 under each Grant were not met. Such grant of shares on account of the Grants will be made in accordance with the applicable award terms and conditions. For clarity, if you are provided notice of termination during fiscal year 2024, you will not be entitled to any vesting with respect to a performance period scheduled to end after fiscal year 2024. |
Your employment with the Company will be terminated (the “Termination Date”) on the date after you receive actual shares of the each of the Grants for performance targets for FY24 (or that a determination was made by the Company’s Board of Directors or applicable committee thereof, that the performance targets for FY24 under each Grant were met). On or promptly after the Termination Date, you will receive your final base salary earned (and unpaid) through the Termination Date, any earned but as-yet unpaid bonuses, if any (for FY24 as provided above in this letter agreement), unpaid expense reimbursements and vested benefits to which you are entitled under the terms of any Company employee benefit plan (which compensation and benefits will be paid to you or your estate in connection with your ceasing to be employed without regard to the reason for such cessation).
For purposes of this letter agreement, “Determination Date” means the date that the Company’s Board of Directors (or applicable committee thereof) makes the vesting determination under the Grants with respect to the performance periods thereunder ending with or in fiscal year 2024. The Determination Date will occur no later than the time that the Company announces its audited results for fiscal year 2024. In all cases, the Determination Date, as well as any payment of any Company bonus for fiscal year 2024 and any payment of shares earned pursuant to the Grants as provided above, will be made not later than 2-1/2 months after the end of fiscal year 2024.
Our commitment in this letter agreement is in addition to, and does not replace or amend, any agreement between you and the Company, including the terms of any Grant document (other than as explicitly provided above with respect to each of the Grants); provided, however, that if in the period between the Notice Date and the Termination Date you were not required to come to work or perform any tasks for a period of six months our more, you will not receive any additional severance pay upon your separation from the Company pursuant to any Company policy or practice (except that in the event of a change in control of the Company, the severance provisions of the Employment Letter, or your change in control agreement, if any, shall continue to apply in accordance with and subject to their applicable terms). This letter agreement does not alter the “at will” nature of your employment, and the Company or you may terminate your employment at any time and for any reason (or for no reason), with or without advance notice.
2 |
Again, we are very pleased to continue to support your leadership role with the Company. If you agree with the terms outlined herein, please return to me an executed copy of this letter.
Sincerely yours,
LANTRONIX, INC.
BY:
Name:
Title
ACCEPTED AND AGREED TO:
Signature: ____________________________________
Name: [Full Name]
Date: _________________________________________
3 |
1V-%PL5_"W_(J:5_UZQ_^@BH?%7AR'Q'
MI30'"74>6@E_NMZ'V/?_ .M6I81I%I]O'&BHBQ@*JC QT JS2&<#H.HGQ'H
M][X5UHM%J42&,E_O,!T;W(./KP:K>'/$K^%'/A[Q$CPK"3Y%P%)7;G]1Z'\#
M757EE:'Q%!=&UA^T97][Y8W]QUZ]*G\16EM=:/-]HMXIMBY7S$#;3[9IB*MS
MXV\.VT!E.IPR<9"1?,Q_ 5S6CQWGC3Q7%KUS T&EV1_T96_C(Z?7GDGV KGO
M"UE:W'B$1S6T,D>_[KQ@C\C7LB(L:!$4*JC 4# HV#
Cover |
Jul. 05, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jul. 05, 2023 |
Entity File Number | 1-16027 |
Entity Registrant Name | LANTRONIX, INC. |
Entity Central Index Key | 0001114925 |
Entity Tax Identification Number | 33-0362767 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 48 Discovery |
Entity Address, Address Line Two | Suite 250 |
Entity Address, City or Town | Irvine |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92618 |
City Area Code | 949 |
Local Phone Number | 453-3990 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | LTRX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
#AWNC,\DUO[VHI(Q:$J\F)Z&1
M O7R='J_A#A2=,@5=>\8)Y>7]37*F?.%XM4UOS6W!P1U@*%C-_P(-TG$)0@C $9N/:8#[>W(#YQ
ML Q /:*SOF')C4 R,V@DE2;@F,W%P^[HYG3NAE8'VW)L-[3$F^7.WIOHI
M/Q+&/!3_![AO;\6"_9=G.4(R:8 !AAS&1$DCMA_9+EMTFM)1*S,K(&&%'Y$"
M09U7,3!+\QU[69;J89E23B66F(8M-GZ>/-K5,Q#Q>")2 01-YSWD3*)YA9S
M3[J^>>9LBY=3[(M+=JXN,%3K>Q"#^+T?TCX*VVI$K*^0[C_1'WWJ,?].OK/%AWOCJY6XZNC88Y-\Y9^V6/^A.-.Z>/>Q[AY^\FQ_.YWSI
MJWU1SS:OV(CJQ?I#]IWSH?O./6M]U/>Y]_#IOI-[Q\I<*WZZR)^W6MJE-^CK
MMO69ZO34JT\^=W].[O42O^E\H_I?T_?-\JE^Q9A^>J?E!EW_>SO;_-YR3D>'
MN?LO6:,T/C6_?!O89X;7N=BG$^OGUQ^EJQ^U3Z7^A5_Z=O[ QN/.\&KJ]_]J
M-/L/_OV9]:'=N/_^V7:+]T,^,?[ZUBU\U+NCKY8USA[6.I-2O7%U\WE\5W^X
M^$"_7P\?_JI=?AE\__3Q;<#WX.__ U!+ P04 " ! @^56)9A8'DL, "^
M1P % &QA;G1R;VYI>%]E>#$P,#$N:'1M[5QM;]LX$OYNP/^!Y\,6,>"\
M=Q>[MAO B=,VAVP2)-Z]*Q:+!2W1-AM9U%)4'-^OOYDA*4NRDZ9[: